Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International, Inc. (SSII) delivers advanced surgical robotics solutions through its SSi Mantra platform and SSi Mudra instruments, focusing on affordable minimally invasive procedures. This news hub provides investors and healthcare professionals with essential updates on the company's financial developments, technological advancements, and global market strategies.
Key resources include earnings reports, regulatory milestone announcements, and partnership disclosures. Track updates on robotic surgery system enhancements, international expansion initiatives, and clinical validation progress. All content is curated to support informed analysis of SSII's position in the medical robotics sector.
Discover official press releases covering product launches, executive appointments, and strategic collaborations. The repository maintains strict compliance with financial disclosure standards, offering neutral reporting on operational achievements and market developments.
Bookmark this page for streamlined access to SS Innovations' latest corporate news. Combine regular visits with portfolio monitoring tools for comprehensive tracking of this innovative surgical robotics provider.
SS Innovations International (OTC: SSII) has achieved a significant milestone by successfully performing India's first North-to-South robotic cardiac telesurgery using its SSi Mantra 3 Surgical Robotic System. The procedure connected the company's headquarters in Gurugram to Aster CMI Hospital in Bengaluru, spanning over 2,000 kilometers.
The 2-hour-40-minute surgery involved closing a complex Atrial Septal Defect in a 35-year-old patient. Led by Dr. Sudhir Srivastava from Gurugram and supported by Dr. Arul Furtado's team in Bengaluru, the procedure demonstrated exceptional precision with minimal latency.
The SSi Mantra 3, India's first CDSCO-approved surgical robotic system for telesurgery, represents a significant advancement in making specialized surgical care accessible across long distances. This achievement follows previous successful telesurgeries spanning 40 km and 286 km, marking a substantial leap in remote surgical capabilities.
SS Innovations International (OTC: SSII) unveiled its groundbreaking SSI Mantra Tele-Sync Mobile Unit (SSI MantraM) at the Second Global Multi-Specialty Robotic Surgery Conference in Gurugram, India. This first-of-its-kind mobile tele-surgical unit integrates the SSi Mantra 3 Surgical Robotic System with high-speed connectivity to enable remote surgical procedures.
The conference attracted over 1,200 medical professionals. The SSI MantraM is designed to provide robotic-assisted surgery to underserved communities through telesurgery capabilities and real-time collaboration between remote and on-site surgical teams. Notably, the SSi Mantra 3 system is the only robotic system globally to receive CDSCO regulatory approval for telesurgery and tele-proctoring.
The system features 3-5 robotic arms, 3D 4K monitoring, and supports over 40 different types of robotic endo-surgical instruments across various specialties. The company anticipates receiving FDA and CE Mark approval in the second half of 2025.
SS Innovations International (OTC: SSII) announced its 2nd Global Multi-Specialty Robotic Surgery Conference (SMRSC 2025) to be held in Gurugram, India, from March 7-9, 2025. The conference will showcase the company's SSi Mantra 3 Robotic Surgical System, which has already facilitated over 3,200 surgeries across 70+ hospitals globally.
The event will feature live robotic surgeries in multiple specialties and the launch of the SSi Mantra Mobile Unit, a surgical bus designed to expand access to robotic surgical care in underserved areas. The SSi Mantra 3 is notably the only robotic system worldwide with regulatory approval for telesurgery and tele-proctoring from CDSCO, enabling remote surgeries and medical education.
The system features 3-5 robotic arms, 3D 4K monitoring, and over 40 different types of robotic endo-surgical instruments. The company anticipates receiving FDA and CE Mark approvals in the second half of 2025.
SS Innovations International (OTC: SSII) has achieved a historic milestone in global healthcare by successfully performing the world's first robotic cardiac telesurgeries using its SSi Mantra 3 Surgical Robotic System. The procedures, including a robotic-assisted Internal Mammary Artery Harvesting and a Robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB), were conducted remotely between Gurugram and Jaipur, India, spanning 286 kilometers with a latency of only 40 milliseconds.
This breakthrough was made possible due to the recent approval from the Central Drugs Standard Control Organization (CDSCO), India's regulatory authority, making SS Innovations the first in India to receive such approval for telesurgery and teleproctoring capabilities. The SSi Mantra 3 system has been clinically validated in over 80 different types of surgical procedures in India and is awaiting FDA and CE Mark approvals by the second half of 2025.
The success of these telesurgeries underscores the potential of advanced surgical technology in overcoming geographical barriers, enabling timely and precise medical care. It also marks a significant step forward in making high-quality healthcare accessible to underserved communities, particularly in rural areas.
SS Innovations International (SSII) announced the completion of BDO India LLP's re-audit of its 2022-2023 financial statements, following the termination of its previous auditor BF Borgers CPA PC. The re-audit revealed material errors in prior statements, leading to restated financials showing improved metrics: shareholders' equity increased by $5.42 Million to $19.72 Million, and working capital surplus rose by $3.85 Million to $12.96 Million.
The company has withdrawn its Form S-1 Registration Statement and plans to uplist to NASDAQ without completing the previously contemplated offering. SSII reports over 2,500 completed robotic surgical procedures using its SSi Mantra Surgical Robotic System, with systems now installed in 5 countries, including recent expansion to Indonesia where it completed the country's first robotic cardiac surgery.
SS Innovations International (OTC: SSII) has achieved a significant milestone by becoming the first company in India to receive CDSCO regulatory approval for Telesurgery and Teleproctoring capabilities of its SSi Mantra surgical robotic system. This breakthrough enables remote surgical procedures and training, particularly benefiting patients in rural areas with access to specialized medical care.
The SSi Mantra system features advanced capabilities including 3-5 robotic arms, a 3D 4K monitor, and over 40 different types of robotic endo-surgical instruments. The system has been clinically validated in India across more than 80 different surgical procedures. The company is currently seeking FDA and CE Mark approvals, anticipated in the second half of 2025.
SS Innovations International (OTC: SSII) has achieved a significant milestone by completing Indonesia's first robotic cardiac surgery using its SSi Mantra Surgical Robotic System at Harapan Kita National Cardiac Hospital in Jakarta. Dr. Sudhir Srivastava, the company's Founder and CEO, performed the first Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB), followed by 7-8 additional robotic-assisted procedures. The procedures included bilateral IMA CABG, ASD Repair, and TECAB surgeries. This achievement marks a significant advancement for Indonesia's healthcare sector, with its population of over 284 million and nearly 3,000 hospitals.
SS Innovations International, Inc. (OTC: SSII) has announced the addition of Tim Adams to its Board of Directors as an Independent Director. Mr. Adams, a healthcare executive with over 40 years of experience, currently serves as a Regional Operating Officer at Ascension, overseeing high-growth Horizontal Business Units. His extensive background includes leadership roles at major healthcare providers such as Tenet Healthcare , Community Health Systems, and HCA.
Dr. Sudhir Srivastava, SS Innovations Chairman and CEO, expressed enthusiasm about Mr. Adams joining during a phase of global growth. The company recently launched the SSI Mantra 3, an advanced surgical robotic system designed for multi-specialty usage. SS Innovations is currently seeking FDA approval and anticipates receiving marketing approval in the second half of 2025.
SS Innovations International, Inc. (OTC: SSII) has announced a significant milestone: over 2,000 successful robotic surgeries performed using its SSi Mantra Surgical Robotic System, primarily in India. This achievement underscores the company's commitment to making advanced surgical technologies accessible globally.
The SSi Mantra system has been praised for its ergonomic design and precise controls, facilitating minimally invasive procedures and improving patient outcomes. It has been installed in numerous Tier 2 and Tier 3 cities across India, as well as in Nepal, marking the country's first surgical robot.
Of the 2,000 surgeries, 123 were cardiac cases, demonstrating the system's versatility. The company's focus on 'democratizing access' and 'decentralizing excellence' in healthcare is evident in its efforts to make world-class robotic surgery affordable and accessible to a larger global population.
SS Innovations International, Inc. (OTC: SSII) has provided an update on its progress towards FDA approval for the SSi Mantra Surgical Robotic System. The company completed its first interactive pre-submission meeting with the FDA earlier this year and received valuable feedback. Based on this, SSII will proceed with a de novo pathway for pre-market submission for numerous indications in parallel.
SSII plans to submit an investigational device exemption (IDE) application in Q1 2025 to initiate clinical trials for various indications including abdominal, pelvis, thoracic, and cardiac procedures. The company expects to secure pre-market approvals by the end of 2025. SSII believes it can meet clinical trial requirements quickly due to the SSi Mantra's demonstrated safety and efficacy in India, where it has already performed all types of surgical procedures for which approval is being sought.